Jagsonpal Pharma: Promoters Report No Share Encumbrance for FY26
Infinity Holdings and associated parties declare no share encumbrance for Jagsonpal Pharmaceuticals Limited during FY26. This disclosure is made as per SEBI Takeover Regulations, ensuring promoter transparency. The announcement was broadcast on April 6, 2026.
This is a standard disclosure under SEBI regulations and does not indicate any significant change in the company's shareholding structure or operational performance.
The announcement is a routine regulatory filing confirming no encumbrance of shares. It does not contain any positive or negative financial or operational news.
Infinity Holdings, along with persons acting in concert with Jagsonpal Pharmaceuticals Limited, has submitted a disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure confirms that no encumbrance of shares, either directly or indirectly, was made by the promoters during the financial year ended March 31, 2026.
This declaration is in accordance with the SEBI regulations, ensuring transparency regarding shareholding and potential changes in ownership structures. The filing was made to the BSE Ltd and the National Stock Exchange of India Ltd on April 06, 2026.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.